Skip to main content
Brian Till, MD, Oncology, Seattle, WA

Brian Gerald Till MD

Hematologic Oncology


Assistant Professor, Medicine, University of Washington School of Medicine

Join to view full profile
  • 825 Eastlake Ave ESeattle, WA 98109

  • Phone+1 855-557-0555

  • Fax+1 206-606-1025

Dr. Till is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007
  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2005 - 2027
  • PA State Medical License
    PA State Medical License 2002 - 2005
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
    Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
    Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
    Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
    Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020

Grant Support

  • Mechanisms of treatment failure in chimeric antigen receptor T cell therapyFRED HUTCHINSON CANCER CENTER2019–2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: